{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009880","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.854279+00:00","generated_at":"2026-05-16T10:53:35.218798+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE","bullets":["CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.","CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.","Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.","Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.","Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009880","json":"https://secwatch.observer/filing/0001193125-26-009880.json","markdown":"https://secwatch.observer/filing/0001193125-26-009880.md","text":"https://secwatch.observer/filing/0001193125-26-009880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/0001193125-26-009880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/crsp-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:35.218798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}